C19orf52 Inhibitors
C19orf52 inhibitors encompass a range of compounds that target specific signaling pathways or molecules to indirectly impair the functional activity of C19orf52. Staurosporine, a broad-spectrum kinase inhibitor, can inhibit protein kinases pivotal to phosphorylation events that may activate or stabilize C19orf52. Similarly, LY294002 and Wortmannin, both PI3K inhibitors, diminish the PI3K/AKT/mTOR signaling, potentially undermining C19orf52 function if it is contingent on this pathway for activity. Rapamycin's inhibition of mTORC1, a central node in cell growth and metabolism regulation, can affect C19orf52 if its functionality is intertwined with mTORC1 signaling.
Further down the signaling cascade, MEK inhibitors like U0126 and PD98059 directly inhibit the MAPK/ERK pathway, which is critical for cell proliferation and differentiation. If C19orf52 operates within this pathway, its activity would be impeded. In addition, SB203580 and SP600125 target the p38 MAPK and JNK pathways, respectively. These pathways are integral to the cellular stress response, andC19orf52 inhibitors encompass a range of compounds that target specific signaling pathways or molecules to indirectly impair the functional activity of C19orf52. Staurosporine, a broad-spectrum kinase inhibitor, can inhibit protein kinases pivotal to phosphorylation events that may activate or stabilize C19orf52. Similarly, LY294002 and Wortmannin, both PI3K inhibitors, diminish the PI3K/AKT/mTOR signaling, potentially undermining C19orf52 function if it is contingent on this pathway for activity. Rapamycin's inhibition of mTORC1, a central node in cell growth and metabolism regulation, can affect C19orf52 if its functionality is intertwined with mTORC1 signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. It can inhibit a wide range of kinases that may be upstream regulators of C19orf52. If C19orf52 is regulated by protein kinase-mediated phosphorylation, staurosporine would lead to its functional inhibition by preventing its phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of PI3K, which is involved in the PI3K/AKT/mTOR pathway. Inhibition of this pathway can decrease cellular survival signals which, if C19orf52 is involved in cell survival, would result in the inhibition of C19orf52 function due to reduced signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, similar to LY294002, and it disrupts the PI3K/AKT/mTOR pathway, leading to the functional inhibition of C19orf52 if it is associated with this pathway for its activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor which suppresses mTORC1 activity. If C19orf52 function is dependent on mTORC1-mediated signaling, rapamycin would indirectly inhibit C19orf52 by inhibiting the pathway necessary for its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are part of the MAPK/ERK pathway. If C19orf52 is regulated by the MAPK/ERK pathway, U0126 would inhibit C19orf52 function by preventing the activation of this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. Blocking this pathway could inhibit C19orf52 function if C19orf52 is regulated by or associated with this signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which could inhibit C19orf52 if it is involved in stress response pathways regulated by p38 MAPK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is involved in stress and apoptosis signaling pathways. If C19orf52 function is related to these pathways, inhibition of JNK would lead to decreased C19orf52 activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. If C19orf52 is regulated through Src family kinase signaling, dasatinib would inhibit these pathways, leading to reduced C19orf52 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. If C19orf52 is degraded by the proteasome, inhibition with bortezomib would increase C19orf52 levels, but paradoxically it could also lead to decreased functional activity due to the accumulation of misfolded or dysfunctional proteins. | ||||||